BACE1 is a prime target for AD therapy, as it is elevated in the brains of patients with AD, accumulated in the swollen axons and its cleavage of APP is the rate-limiting step in Aβ production [41, 42]. The gene discussed is APP; the disease is Alzheimer disease.